Screener
Ligand Pharmaceuticals LGND Goodwill
Goodwill at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:Goodwill.
The source filing: Ligand Pharmaceuticals’s 10-Q, filed August 7, 2026.
- Filed
- Aug 7, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000886163-26-000044
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Other current assets | 6,191 | 5,785 |
| Total current assets | 1,457,116 | 832,271 |
| Intangible assets, net | 209,244 | 225,438 |
| Goodwill | 101,541 | 101,541 |
| Long-term portion of financial royalty assets, net | 194,228 | 196,877 |
| Noncurrent derivative assets | 17,913 | 15,632 |
| Equity method investments | 42,390 | 46,500 |
| Other investments | 114,483 | 121,451 |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Ligand Pharmaceuticals's goodwill?
- Ligand Pharmaceuticals (LGND) reported goodwill of $101.54M in Q2 2026.
- How has Ligand Pharmaceuticals's goodwill changed year-over-year?
- Ligand Pharmaceuticals's goodwill decreased by 0.0% year-over-year, from $101.54M to $101.54M.
- What is the long-term trend for Ligand Pharmaceuticals's goodwill?
- Over 5 years (2020 to 2025), Ligand Pharmaceuticals's goodwill has grown at a -11.7% compound annual growth rate (CAGR), from $189.66M to $101.54M.
- What does goodwill mean?
- The excess of acquisition cost over the fair value of net identifiable assets acquired — representing brand value, customer relationships, and synergies from past M&A.
Ask your AI about Ligand Pharmaceuticals's goodwill.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude